Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents without reflux, today announced that the company's Surefire Infusion System will be used in the development of the first clinically viable microcatheter-based, minimally invasive treatment for obesity as an alternative to bariatric surgery.
[More]
Rhythm announced today the initiation of an additional Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of chronic constipation. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal motility.
[More]
Most weight-loss plans center around a balance between caloric intake and energy expenditure. However, new research has shed light on a new factor that is necessary to shed pounds: timing. Researchers from Brigham and Women's Hospital (BWH), in collaboration with the University of Murcia and Tufts University, have found that it's not simply what you eat, but also when you eat, that may help with weight-loss regulation.
[More]
Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.
[More]
Rhythm announced today the initiation of a Phase 2 clinical trial with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity.
[More]
The battle of the bulge is on - any movement on the scale yet? "Losing weight is one of the top resolutions made every year, yet only 20 percent of people achieve successful weight-loss and maintenance," says Jessica Bartfield,MD, internal medicine who specializes in nutrition and weight management at the Loyola Center for Metabolic Surgery & Bariatric Care.
[More]
Married for over ten years, Oxnard-based couple Roger and Mayra Rosales have enjoyed their kids and family life. Still, one element greatly detracted from their happiness for years. Both struggled with obesity, along with frequent illnesses which were part and parcel to the excessive weight.
[More]
A new study suggests that increasing the amount of sleep that adults get could lead to reduced food intake, but the hormonal process differs between men and women.
[More]
Rhythm announced today that the company has raised an additional $8 million to complete a $33 million Series B financing.
[More]
Bariatric surgery, which significantly curtails the amount of food a person can eat, is the most effective treatment against obesity and is being recognized as a potentially valuable tool in the fight against diabetes related to obesity.
[More]
Evidence linking partial sleep deprivation to energy imbalance is relevant to weight gain prevention and weight loss promotion. A new study published today in the Journal of the Academy of Nutrition and Dietetics bases this finding on an extensive review of literature published over a fifteen-year period.
[More]
Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis, which demonstrated that RM-131 greatly accelerates gastric emptying in healthy subjects with good tolerability.
[More]
Aeterna Zentaris Inc. today announced that it continues to expect to file a New Drug Application (NDA) early next year, for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD), after receiving notification from the United States Food and Drug Administration (FDA) that Fast Track designation had not been granted.
[More]
Aeterna Zentaris Inc. today announced that the European Patent Office has granted a patent for the use of the ghrelin agonist, AEZS-130, related to methods and kits for use in relation to the diagnosis of growth hormone deficiency in a human or animal subject.
[More]
Ghrelin is a hormone released by the lining of the stomach that promotes feeding behavior. Decreasing ghrelin levels could potentially help combat obesity -- in fact, a vaccine that lowers ghrelin levels in order to reduce appetite is being studied as a treatment for obesity.
[More]
Researchers at The Scripps Research Institute have found new links between a protein that controls our urge to eat and brain cells involved in the development of alcoholism. The discovery points to new possibilities for designing drugs to treat alcoholism and other addictions.
[More]
Aeterna Zentaris Inc. today announced that a first patient has been recruited for a Phase 2A trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia.
[More]
Aeterna Zentaris Inc. today announced that the United States Patent and Trademark Office has granted a patent for the use of its oral ghrelin agonist, AEZS-130 (EP1572) as a diagnostic test for adult growth hormone deficiency.
[More]
Aeterna Zentaris Inc. today announced that it has filed a request with the United States Food and Drug Administration (FDA) for Fast Track designation for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD).
[More]
A pre-diet measurement of two hormones related to weight regulation can help predict which dieters will be more likely to maintain their weight loss and who will not, according to a new study. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.
[More]